Contact
searchSearch
HMP Global
Login

News

David Andorsky, MD
Conference Coverage
Novel Allosteric BCR::ABL1 Inhibitor TERN-701 Demonstrates Encouraging Efficacy for Chronic Myeloid Leukemia: CARDINAL Study
01/05/2026
David Andorsky, MD
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented...
01/05/2026
Oncology
David Andorsky, MD
Conference Coverage
ASC2ESCALATE: Asciminib Demonstrates High Molecular Responses Among Patients With CML-CP
06/06/2025
David J. Andorsky
David Andorsky, MD, shares the results from the ASC2ESCALATE trial which assessed the safety and efficacy of asciminib as second-line treatment for chronic myeloid leukemia in chronic phase among patients intolerant to tyrosine kinase...
David Andorsky, MD, shares the results from the ASC2ESCALATE trial which assessed the safety and efficacy of asciminib as second-line treatment for chronic myeloid leukemia in chronic phase among patients intolerant to tyrosine kinase...
David Andorsky, MD, shares the...
06/06/2025
Oncology
Andreas Hochhaus, MD
Conference Coverage
Asciminib Demonstrates Superior Tolerability vs Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
06/06/2025
Andreas Hochhaus, MD
Andreas Hochhaus, MD, shares results from the ASC4START trial which found asciminib to be more tolerable than nilotinib among patients with newly diagnosed chronic phase chromic myeloid leukemia.
Andreas Hochhaus, MD, shares results from the ASC4START trial which found asciminib to be more tolerable than nilotinib among patients with newly diagnosed chronic phase chromic myeloid leukemia.
Andreas Hochhaus, MD, shares...
06/06/2025
Oncology
News
Real-World Comparison of Dasatinib and Nilotinib as Second-Line Therapy for Chronic Phase Chronic Myeloid Leukemia
03/25/2025
Emily Estrada
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
According to results from a real-world retrospective analysis, dasatinib and nilotinib demonstrate comparable efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase.
According to results from a...
03/25/2025
Oncology
News
Real-World Efficacy of Asciminib in Chronic Myeloid Leukemia After Multiple Tyrosine Kinase Inhibitors
03/24/2025
Emily Estrada
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with chronic myeloid leukemia in chronic phase previously treated with tyrosine kinase inhibitors, asciminib demonstrated efficacy and tolerability in a real-world setting.
For patients with chronic...
03/24/2025
Oncology
Fadi Haddad, MD
Videos
Latest Strategies for Treating Patients With Chronic Myeloid Leukemia
02/24/2025
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most...
02/24/2025
Oncology
Jorge Cortes, MD
Videos
Asciminib Demonstrates Favorable Safety and Tolerability for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Compared With Tyrosine Kinase Inhibitor Therapy
01/29/2025
Jorge Cortes, MD
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine...
01/29/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
FDA Approval
FDA Grants Accelerated Approval to Frontline Asciminib for Patients With Ph+ Chronic Myeloid Leukemia
10/29/2024
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated...
10/29/2024
Oncology
News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use